Abstract:Currently, karyotype analysis for chromosome translocation of 9 and 22 and FISH or gene amplification-based technique for bcr-abl fusion gene have been the major strategies for the diagnosis and disease status evaluation of bcr-abl positive leukemias. However, the method for aberranttyrosine kinase level, which is the reflection of cellular function, is limited to the detection of the level of phosphorylated tyrosine by Western blot. This method is technically laborious, costly and sometimes leads to feigned results. We thus tried to set up a flow cytometry based technique to evaluate its possible utilization in the diagnosis and the evaluation of the disease status in bcr-abl positive leukemias. Mononuclear cells from heparinized bone marrow of patients were collected. After treatment with hemolysin, 106 cells were fixated, permeabilized and then incubated with fluorescein isothiocyanate (FITC) conjugated anti-phosphotyrosine monoclonal antibody (PY20). Fluorescence conjugated microspheres were put in the system as a calibration factor in order to provide a quantitive value for the sake of comparison with different detections. The geomean value of fluorescent microsphere was adjusted to 20 in each case and the ratio of the geomean value of each detected sample to 20 was read as relative value of phosphotyrosine level. This relative value was used in statistical analysis. The human leukemia cell line Mo7e and its derivation Mo7e P210 expressing human bcr-abl fusion gene were employed as negative and positive samples to optimize the experimental conditions. Phosphotyrosine protein in fresh bone marrow cells from patients with chronic myelogenous leukemia (CML) in different phases, bcr-abl positive acute lymphoblastic leukemia (ALL) and normal controls were evaluated by semi-quantitative analysis. A total of 32 CML, including 22 in chronic phase(CP), 3 in accelerated phase(AP) and 7 in blast crisis(BC) were enrolled in this study. Four patients with bcr-abl positive ALL were also included. It was found that there was a significantly different geomean value between Mo7e and Mo7e P210. The relative values of phosphotyrosine levels were different between bcr-abl positive samples and normal controls. The value was 756±144, 865±96, 847±105 and 819±225 with CML patients in CP,AP,BC groups and ALL group respectively, while it was only 18±7 in control group. Statistical analysis showed a significant difference among these five groups. The comparison between each two groups showed a significant difference between each bcr-abl positive group and control group (P< 0.01). There were also significant differences between the AP/CML, BC/CML or ALL group and CP/CML group(P< 0.01). We observed a trend that the value of a given patient escalated with disease progression. In a patient who was on imatinib treatment for one month, there existed two peaks of cells with different fluorescent intensity, each representing a bcr-abl positive or negative cell group, coincident with the FISH result of 158 bcr-abl positive cells in 1000 detected cells. We concluded that flow cytometry analysis of the phosphotyrosine level could be used as an adjuvant technique for the diagnosis and differential diagnosis of bcr-abl positive leukemias. It may also play an important role in the evaluation of disease status or in the judgment of therapeutic efficacy during patient follow-up.

Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia

Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

Flow cytometric assay of phosphotyrosine levels in Bcr-Abl-positive chronic myelogenous leukemias: a potential prognostic marker

Quantitative detection of BCR–ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment

Advantages of Digital PCR in the Detection of Low Abundance BCR-ABL1 Gene in Patients with Chronic Myeloid Leukemia

[Role of Flow Cytometry in the Diagnosis of Chronic Myeloid Leukemia].

Diagnostic Application of Flow Cytometry in Phosphotyrosine Level Detection and Disease Status Evaluation in Patients with Bcr-abl Positive Leukemia.

Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia.

Analysis of Two Mutations in the BCR-ABL Fusion Gene Relevant for Monitoring Chronic Myeloid Leukemia Patients

Rapid detection of BCR-ABL fusion genes using a novel combined LUX primer, in-cell RT-PCR and flow cytometric method

An Ultrasensitive Fluorescence Sensing Strategy for Detection and in Situ Imaging of Chronic Myeloid Leukemia-Related BCR-ABL1 Mrna

Application of real-time quantification polymerase chain reaction in detecting the expression of BCR-ABL in chronic myelogenous leukemia cells

Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array

Study on the cases with BCR/ABL fusion gene positively detected by fluorescence in situ hybridization

Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression

Measurable Residual Disease Analysis by Flow Cytometry and Correlation With Molecular Measurable Residual Disease in Acute Promyelocytic Leukemia: A Real-World Prospective Study

Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.

[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].

[Clinical application of BCR/ABL probes in myeloproliferative disorders].

CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemia